MapLight Halts Early Work to Focus on Lead Candidate; ADC Therapeutics Reassesses Zynlonta
MapLight Therapeutics is pausing its preclinical and discovery research to redirect resources toward advancing its lead drug candidate, ML-007C-MA, for schizophrenia and Alzheimer's disease psychosis. Meanwhile, ADC Therapeutics is evaluating the future of its approved therapy Zynlonta.
Related stories
Biotech releases Phase 1 respiratory therapy results following premature poster exposure · Drug development
Anthropic's Claude Takes the Wheel in De Novo Protein Design · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlonta.” Browse more stories.